Metraipolis › archive › dc_08b6e9ae16ef

Delgocitinib 2% cream: a promising FDA-approved therapy for moderate-to-severe chronic hand eczema — Europe PMC PMID:41181467

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41181467
DOI
10.1097/ms9.0000000000003771
License (as archived)
solo-consultazione
Archived
2026-11-10T07:53:25.429Z
SHA-256 of the archived text
6e5559752cec0eacff43af2c7e87fef92ffc45c9871425a0fd703898d454edbb
Stable URL of this page
https://metraipolis.com/documento/dc_08b6e9ae16ef

How to cite

Delgocitinib 2% cream: a promising FDA-approved therapy for moderate-to-severe chronic hand eczema — Europe PMC PMID:41181467 — Europe PMC (en), https://europepmc.org/article/MED/41181467 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_08b6e9ae16ef (Metraipolis archive dc_08b6e9ae16ef, sha256 6e5559752cec0eacff43af2c7e87fef92ffc45c9871425a0fd703898d454edbb)
BibTeX
@misc{dc08b6e9ae16ef,
  title = {Delgocitinib 2% cream: a promising FDA-approved therapy for moderate-to-severe chronic hand eczema — Europe PMC PMID:41181467},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41181467},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_08b6e9ae16ef; sha256 6e5559752cec0eacff43af2c7e87fef92ffc45c9871425a0fd703898d454edbb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41181467. Agents can read the archived copy with the MCP tool read_document.